Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that CF101, administered orally, will reduce intraocular
pressure in patients with ocular hypertension and/or glaucoma. Eligible patients with
elevated intraocular pressure will be evaluated and treated by ophthalmologist investigators,
and will receive either CF101 pills or placebo (dummy) pills twice daily for 16 weeks. Ocular
pressure, visual fields, and other aspects of safety and effectiveness will be monitored on a
regular basis.